Akebia Therapeutics, Inc.
AKBA
NASDAQ·Healthcare·Biotechnology·Mkt cap $261.5M
$0.97
▼ -0.87%
P/E
-9.03
Mkt Cap
$261.5M
52-Wk Range
$0.81–$3.20
52-Week Range
$0.81 - $3.20
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 68.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Established FDA-approved product (Auryxia) generating revenue and market presence
- Strategic partnerships with major global pharmaceutical companies reducing development risk and expanding market access
- Focused pipeline targeting high-prevalence kidney disease indications with significant unmet medical needs
- Oral formulation of vadadustat offering convenience advantages over injectable competitors
Bear Case
1 risk
- Low volatility (beta 0.2).
Growth
Mild headwinds expected
Strong revenue growth (47% YoY)
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Stable
+4.2% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying AKBA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 9, 2026
AUG 5, 2026
Reported EPS of -$0.02 vs -$0.04 consensus (+52.4% surprise). Revenue of $49.1M vs $48.9M expected (+0.6%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+52.4%
Revenue trend · last 8Q
—
-17%
+76%
+43%
+57%
+24%
-7%
-21%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$37.4M
$46.5M
$57.3M
$62.5M
$58.8M
$57.6M
$53.5M
$49.1M
Margins · last 8Q
Gross
78.8%
Operating
-12.9%
Profit
-18.1%
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Jul 1, 2026
vs Industry
How AKBA stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related